Skip to main content
Fig. 3 | Pediatric Rheumatology

Fig. 3

From: Efficacy and safety of thalidomide in children with monogenic autoinflammatory diseases: a single-center, real-world-evidence study

Fig. 3

Time courses for CRP (A) and ESR (B) for each disease. The data were taken at baseline, 3 months before thalidomide and at months 3, 6, 9, and 12 on thalidomide. The color difference outlines the difference in disease types, and the numbers are P values from the paired test for each patient. P < 0.05 was considered statistically significant. Points on lines represent the mean values of the inflammatory index for each disease

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096